-
公开(公告)号：US20230159633A1
公开(公告)日：2023-05-25
申请号：US17992369
申请日：2022-11-22
Applicant: Janssen Biotech, Inc.
Inventor： Matthew Germinaro , Kuan-hsiang Gary Huang , Hongyan Zhang
IPC: C07K16/24 , A61K45/06 , A61K39/395 , A61P1/04 , A61K31/519 , C07K16/28
CPC classification number: C07K16/244 , A61K45/06 , A61K39/3955 , A61P1/04 , A61K31/519 , C07K16/2887 , A61K2039/545
Abstract: A method of treating ulcerative colitis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.
-
公开(公告)号：US20240199734A1
公开(公告)日：2024-06-20
申请号：US18517248
申请日：2023-11-22
Applicant: Janssen Biotech, Inc.
Inventor： Matthew Germinaro , Kuan-hsiang Gary Huang , Hongyan Zhang
CPC classification number: C07K16/244 , A61K9/0019 , A61P1/04 , A61K39/00 , A61K2039/505 , C07K2317/21
Abstract: A method of treating ulcerative colitis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.
-
Patent Agency Ranking
3.发明公开公开(公告)号：US20240010718A1
公开(公告)日：2024-01-11
申请号：US18327577
申请日：2023-06-01
Applicant: Janssen Biotech, Inc.
Inventor： Matthew Germinaro , Christopher O'Brien , Jacqueline Perrigoue
IPC: C07K16/24 , A61K9/00 , A61P1/04 , A61P29/00 , A61K39/395
CPC classification number: C07K16/244 , C07K16/241 , A61K9/0019 , A61P1/04 , A61P29/00 , A61K39/395 , C07K2317/31 , C07K2317/565 , A61K2039/545
Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor, such as an anti-TNF-α antibody (e.g., golimumab).
-
公开(公告)号：US12258393B2
公开(公告)日：2025-03-25
申请号：US17325743
申请日：2021-05-20
Applicant: Janssen Biotech, Inc.
Inventor： Matthew Germinaro , Christopher O'Brien , Jacqueline Perrigoue , Marion Vetter
Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor, such as an anti-TNF-α antibody (e.g., golimumab).
-
公开(公告)号：US20240141032A1
公开(公告)日：2024-05-02
申请号：US17974956
申请日：2022-10-27
Applicant: Janssen Biotech, Inc.
Inventor： Matthew Germinaro , Mobolaji Olurinde , Aparna Sahoo , Jacqueline Yee , Omoniyi Adedokun
CPC classification number: C07K16/244 , A61P37/02 , A61K2039/505
Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial subcutaneous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.
-
公开(公告)号：US11780911B2
公开(公告)日：2023-10-10
申请号：US16880118
申请日：2020-05-21
Applicant: Janssen Biotech, Inc.
Inventor： Matthew Germinaro , Christopher O'Brien , Jacqueline Perrigoue
CPC classification number: C07K16/244 , A61K9/0019 , A61K39/395 , A61P1/04 , A61P29/00 , C07K16/241 , A61K2039/507 , A61K2039/545 , C07K2317/31 , C07K2317/565 , C07K2317/76
Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor, such as an anti-TNF-α antibody (e.g., golimumab).
-
公开(公告)号：US20220372129A1
公开(公告)日：2022-11-24
申请号：US17748629
申请日：2022-05-19
Applicant: Janssen Biotech, Inc.
Inventor： Matthew Germinaro , Christopher O'Brien , Jacqueline Perrigoue , Marion Vetter
IPC: C07K16/24 , A61P1/04 , A61K38/17 , A61K39/395
Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNFα inhibitor, such as an anti-TNFα antibody (e.g., golimumab).
-
-
-
-
-
-
Search Results
7
records
(took 0.018 seconds)
